<DOC>
	<DOCNO>NCT00191724</DOCNO>
	<brief_summary>An exploratory , multicenter , randomize , placebo-controlled , double blind , dose escalation study compare standard therapy submassive pulmonary embolism ( Enoxaparin sodium ) combine therapy Drotrecogin alfa ( activate ) plus Enoxaparin sodium .</brief_summary>
	<brief_title>Adjuvant Treatment Pulmonary Embolism With Drotrecogin Alfa ( Activated ) : Phase II Exploratory Study</brief_title>
	<detailed_description />
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Drotrecogin alfa activate</mesh_term>
	<mesh_term>Protein C</mesh_term>
	<criteria>Patients symptom acute pulmonary embolism ( PE ) , without indication fibrinolytic therapy echocardiographic evidence right ventricular dysfunction ( submassive PE ) within 48 hour onset symptom Clinical symptom Pulmonary embolism le 48 hour Patients symptom Pulmonary embolism 48 hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>